Press releases

Regulatory

December 21, 2016

Oasmia Pharmaceutical Reports Positive Results from Study on Weekly Administration of Apealea® (Paclical®)

Regulatory

December 7, 2016

Oasmia Pharmaceutical AB’s Warrant Programs Fully Subscribed

Regulatory

December 2, 2016

Interim report for the period May – October 2016

Regulatory

November 22, 2016

Communiqué from Extraordinary General Meeting 2016

Regulatory

November 2, 2016

Nexttobe Extends Loan to Oasmia Pharmaceutical

Regulatory

November 1, 2016

Oasmia Pharmaceutical Announces Change in Ownership

Regulatory

October 31, 2016

Change in number of shares and voting rights in Oasmia Pharmaceutical AB (publ)

Regulatory

October 26, 2016

Oasmia convenes an extraordinary general meeting on the 21 November, 2016

Regulatory

October 24, 2016

Oasmia issues new shares for acquiring an asset corresponding to SEK 25 million

Regulatory

October 24, 2016

Oasmia successfully completes private placement of SEK 70 million

Regulatory

October 24, 2016

Oasmia Pharmaceutical intends to convene an extraordinary general meeting

Regulatory

October 24, 2016

Oasmia enters into collaboration agreement for novel cancer project

Regulatory

October 22, 2016

Oasmia announces private placement of new shares

Regulatory

October 21, 2016

Oasmia in discussions concerning acquisition of novel cancer project

Regulatory

September 27, 2016

Communiqué from Oasmia’s Annual General Meeting 2016

Regulatory

September 2, 2016

Interim report for the period May – July 2016

Regulatory

August 31, 2016

Oasmia Pharmaceutical AB Appoints Fredrik Gynnerstedt as Chief Financial Officer

Regulatory

August 26, 2016

Notice convening the Annual General Meeting of Shareholders in Oasmia Pharmaceutical AB

Regulatory

July 8, 2016

The Oasmia Pharmaceutical Annual Report is now published

Non Regulatory

June 10, 2016

Oasmia successfully completes a private placement of new convertible instruments in a total amount of SEK 42,000,000

Non Regulatory

June 3, 2016

Year-end report for the fiscal year May 1, 2015 – April 30, 2016

Non Regulatory

June 3, 2016

Oasmia Pharmaceutical announces early publication of Annual Report

Non Regulatory

May 26, 2016

Oasmia Pharmaceutical to Identify International Partners for Marketing, Distribution and new Product Development based on XR-17

Non Regulatory

May 11, 2016

Clarification of article in BioPharm Insight

Non Regulatory

April 29, 2016

Change in number of shares and voting rights in Oasmia Pharmaceutical AB (publ)

Non Regulatory

April 27, 2016

Oasmia Pharmaceutical Announces Positive Overall Survival Results from Phase III Study of Paclical/Apealea for Treatment of Ovarian Cancer

Non Regulatory

April 15, 2016

Oasmia successfully completes private placements of new convertible instruments and new shares in the total amount of SEK 45,5 million

Non Regulatory

April 5, 2016

Oasmia Pharmaceutical Reports Positive Clinical Study Results for Proprietary XR-17 Nanotechnology

Non Regulatory

March 30, 2016

Oasmia Pharmaceutical Announces Enrollment of First Patient in Clinical Study with Docecal, a Novel Formulation of Docetaxel

Non Regulatory

March 10, 2016

Clarification regarding Press Release about Ovarian Cancer Market

Non Regulatory

March 10, 2016

Oasmia Pharmaceutical Seeks to Fill Void in Ovarian Cancer Treatment Market Indicated in Recent National Academy of Medicine Report

Non Regulatory

March 3, 2016

Interim report for the period May 2015 – January 2016

Non Regulatory

February 29, 2016

Oasmia Pharmaceutical Reissues Executive Summary

Non Regulatory

February 24, 2016

Oasmia Pharmaceutical AB Provides Updates to Clinical Program Development

Non Regulatory

February 8, 2016

Oasmia Has Submitted a Marketing Authorization Application to the European Medicines Agency for Its Lead Cancer Product Apealea® (Paclical®)

Non Regulatory

February 4, 2016

Oasmia Pharmaceutical to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference and BIO CEO & Investor Conference in New York

Regulatory

February 2, 2016

Oasmia Pharmaceutical Makes Key Hires; Strengthens Organizational Structure Entering Commercial Phase

Non Regulatory

January 11, 2016

Oasmia Pharmaceutical AB (Nasdaq: OASM) to Ring the Nasdaq Stock Market Opening Bell on January 11

Non Regulatory

January 4, 2016

Oasmia Submits Application for Market Approval of its Next Generation Anti-Cancer Drug Doxophos® in Russia